Literature DB >> 7826144

Silicon nephropathy and myeloperoxidase antibodies.

A Chevailler, F Carrere, G Renier, D Hurez, J F Subra, P Reboul, P Riberi, C Masson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826144      PMCID: PMC1005465          DOI: 10.1136/ard.53.11.781-b

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Circulating antinuclear and rheumatoid factors in coal miners. A prevalence study in Pennsylvania and West Virginia.

Authors:  M Lippmann; H L Eckert; N Hahon; W K Morgan
Journal:  Ann Intern Med       Date:  1973-12       Impact factor: 25.391

2.  [Rapidly progressive glomerulonephritis in pneumoconiotic coal miners].

Authors:  M Dracon; C Noël; B Wallaert; P Dequiedt; G Lelièvre; A Tacquet
Journal:  Nephrologie       Date:  1990

3.  Anti-myeloperoxidase antibodies and associated diseases.

Authors:  A Chevailler; J F Subra; G Renier; F Carrère; D Hurez
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

4.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; P C Limburg; M van der Giessen; M G Huitema; M I Koolen; R J Hené; T H The; G K van der Hem
Journal:  Arthritis Rheum       Date:  1990-08

5.  Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study.

Authors:  G Gregorini; A Ferioli; F Donato; P Tira; L Morassi; R Tardanico; L Lancini; R Maiorca
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

6.  Silica-stimulated monocytes release fibroblast proliferation factors identical to interleukin 1. A potential role for interleukin 1 in the pathogenesis of silicosis.

Authors:  J A Schmidt; C N Oliver; J L Lepe-Zuniga; I Green; I Gery
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

7.  Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica.

Authors:  J Sanchez-Roman; I Wichmann; J Salaberri; J M Varela; A Nuñez-Roldan
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

8.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

9.  Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model.

Authors:  E Brouwer; M G Huitema; P A Klok; H de Weerd; J W Tervaert; J J Weening; C G Kallenberg
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  9 in total
  5 in total

Review 1.  ANCA-associated diseases and silica exposure.

Authors:  G Gregorini; P Tira; J Frizza; P C D'Haese; M M Elseviers; G Nuyts; R Maiorca; M E De Broe
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

2.  Microscopic polyangiitis after silicone breast implantation.

Authors:  Masayuki Iyoda; Jyun Ito; Hisako Nagai; Kasumi Sato; Aki Kuroki; Takanori Shibata; Kozo Kitazawa; Tetsuzo Sugisaki
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  Lymphopenia in occupational pulmonary silicosis with or without autoimmune disease.

Authors:  J F Subra; G Renier; P Reboul; F Tollis; R Boivinet; P Schwartz; A Chevailler
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  Antimyeloperoxidase antibodies in individuals with occupational exposure to silica.

Authors:  I Wichmann; J Sanchez-Roman; J Morales; M J Castillo; C Ocaña; A Nuñez-Roldan
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

Review 5.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.